Fabiana Letizia Cecere
A5046270433- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Occupational and environmental lung diseases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Myasthenia Gravis and Thymoma
- DNA Repair Mechanisms
- Colorectal and Anal Carcinomas
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Pleural and Pulmonary Diseases
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2025
Istituti Fisioterapici Ospitalieri
2019-2024
University of Bologna
2024
Instituto Nazionale Tumori Regina Elena
2017-2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2023
Tumori Foundation
2017-2022
National Cancer Institute
2007-2019
Azienda Ospedaliero-Universitaria Careggi
2010-2019
Institut Català d'Oncologia
2006-2007
Hospital Universitari Germans Trias i Pujol
2006-2007
LBA8505 Background: The vast majority of pts with PM have unresectable disease, due to co-morbidities and/or advanced stage. In PM, standard first line treatment has been C(or carboplatin)P for 20 years but it is usually only moderately efficient, mostly on epithelioid (E)PM, a global median overall survival (mOS) around 12 months (m), an improved quality-of-life (QoL), and mild toxicity. Trial CM743 demonstrated significant improvement in mOS nivolumab/ipilimumab (NI) over CP (18.1 versus...
Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients at least three metastatic sites, brain metastases, and symptoms diagnosis seem to have worse prognosis.Osimertinib became the standard treatment for untreated cancer (aNSCLC) following results reported phase...
Here, we developed an unbiased, functional target-discovery platform to identify immunogenic proteins from primary non-small cell lung cancer (NSCLC) cells that had been induced apoptosis by cisplatin (CDDP) treatment in vitro, as compared with their live counterparts. Among the multitude of identified, some them were represented fragmented apoptotic tumor cells, and acted non-mutated neoantigens (NM-neoAgs). Indeed, only elicited effective multi-specific CD4+ CD8+ T responses, upon a...
ObjectiveTo report outcomes of urgent juxtarenal/pararenal aneurysms (J/P-AAAs) managed by off-the-shelf multibranched thoracoabdominal endografts (Cook, T-branch).MethodsIn this observational, multicenter, retrospective study, patients with J/P-AAAs treated endovascular repair T-branch in 23 European aortic centers, from 2013 to 2023, were analyzed. Contained rupture, presence related symptoms, and aneurysm diameter >70 mm considered as indication for repair. Technical success (TS), spinal...
Introduction: The standard surgical procedures for patients with early-stage NSCLC is lobectomy-associated radical lymphadenectomy performed by using the thoracotomy approach. In last few years, minimally invasive techniques have increasingly strengthened their role in lung cancer treatment, especially early stage of disease. Although lobectomy technique has been accepted, controversy still surrounds lymph node dissection. our study, we analyze rate upstaging non-small cell who underwent...
KRAS G12C mutations are found in about 12-13% of LUAD samples and it is unclear whether they associated with worse survival outcomes resected, stage I LUAD. We assessed KRAS-G12C mutated tumours had DFS when compared to KRAS-nonG12C wild-type a cohort (IRE cohort). then leveraged on publicly available datasets (TCGA-LUAD, MSK-LUAD604) further test the hypothesis external cohorts. In IRE we significant association between mutation multivariable analysis (HR: 2.47). TCGA-LUAD did not find...